Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Bioatla Inc (BCAB)

Bioatla Inc (BCAB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 107,306
  • Shares Outstanding, K 48,336
  • Annual Sales, $ 0 K
  • Annual Income, $ -123,460 K
  • EBIT $ -110 M
  • EBITDA $ -109 M
  • 60-Month Beta 1.03
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 3.17

Options Overview Details

View History
  • Implied Volatility 209.67% ( +31.66%)
  • Historical Volatility 91.59%
  • IV Percentile 75%
  • IV Rank 22.32%
  • IV High 760.51% on 06/28/24
  • IV Low 51.43% on 02/12/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 1,895
  • Volume Avg (30-Day) 514
  • Put/Call OI Ratio 0.10
  • Today's Open Interest 9,977
  • Open Int (30-Day) 9,900

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.35
  • Number of Estimates 1
  • High Estimate -0.35
  • Low Estimate -0.35
  • Prior Year -0.56
  • Growth Rate Est. (year over year) +37.50%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.84 +14.13%
on 10/17/24
2.36 -11.02%
on 11/07/24
+0.05 (+2.44%)
since 10/08/24
3-Month
1.32 +59.09%
on 08/14/24
2.40 -12.50%
on 10/04/24
+0.63 (+42.86%)
since 08/08/24
52-Week
1.14 +84.21%
on 07/09/24
4.02 -47.76%
on 04/04/24
+0.45 (+27.27%)
since 11/08/23

Most Recent Stories

More News
BioAtla Reports Third Quarter 2024 Financial Results and Highlights Recent Progress

BCAB : 2.10 (-5.41%)
BioAtla to Announce Third Quarter 2024 Financial Results and Provide Business Highlights on November 7, 2024

BCAB : 2.10 (-5.41%)
BioAtla Announces Upcoming Poster Presentation at the 39th Society for Immunotherapy of Cancer Annual Meeting

BCAB : 2.10 (-5.41%)
Viatris Announces Appointments of Scott A. Smith and Elisha W. Finney to the Company's Board of Directors

/PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced that Scott A. Smith and Elisha W. Finney have been appointed as...

BCAB : 2.10 (-5.41%)
VTRS : 12.96 (-1.67%)
Himalaya Therapeutics Announces Highlights of Recent Clinical Progress

/PRNewswire/ -- Himalaya Therapeutics ("Himalaya"), a clinical-stage biopharmaceutical company focused on development and commercialization of a novel class of...

BCAB : 2.10 (-5.41%)
Himalaya Therapeutics Announces Interim Phase 2 Results for Mecbotamab vedotin (HTBA3011)

/PRNewswire/ -- Himalaya Therapeutics ("Himalaya"), a clinical-stage biopharmaceutical company focused on development and commercialization of a novel class of...

BCAB : 2.10 (-5.41%)
BioAtla Reports Second Quarter 2022 Financial Results And Highlights Recent Progress

Mecbotamab vedotin (BA3011) Phase 2 preliminary observations in Non-Small Cell Lung Carcinoma (NSCLC) supports advancing to the registrational stage of the...

BCAB : 2.10 (-5.41%)
BioAtla to Announce Second Quarter 2022 Financial Results and Provide Business Highlights on August 9, 2022

SAN DIEGO, Aug. 02, 2022 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of...

BCAB : 2.10 (-5.41%)
BioAtla Reports First Quarter 2022 Financial Results and Highlights Recent Progress

– Mecbotamab vedotin (BA3011) sarcoma Phase 2 top-line interim data support advancing with UPS and osteosarcoma – – Mecbotamab vedotin (BA3011) Phase 2...

BCAB : 2.10 (-5.41%)
BioAtla to Announce First Quarter 2022 Financial Results and Provide Business Highlights on May 4, 2022

SAN DIEGO, April 08, 2022 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of...

BCAB : 2.10 (-5.41%)

Business Summary

BioAtla Inc. is a clinical-stage biopharmaceutical company. It engages in developing a novel class of antibody-based therapeutics for the treatment of solid tumor cancer. BioAtla Inc. is based in SAN DIEGO.

See More

Key Turning Points

3rd Resistance Point 2.72
2nd Resistance Point 2.54
1st Resistance Point 2.38
Last Price 2.10
1st Support Level 2.04
2nd Support Level 1.86
3rd Support Level 1.70

See More

52-Week High 4.02
Fibonacci 61.8% 2.92
Fibonacci 50% 2.58
Fibonacci 38.2% 2.24
Last Price 2.10
52-Week Low 1.14

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar